Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc. (DRUG.CN) Financial Performance & Income Statement Overview
Analyze Bright Minds Biosciences Inc. (DRUG.CN) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Bright Minds Biosciences Inc. (DRUG.CN) Income Statement & Financial Overview
Explore comprehensive income reports for Bright Minds Biosciences Inc. DRUG.CN, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $18113.00 | $18112.00 |
| Gross Profit | $0.00 | $0.00 | -$18113.00 | -$18112.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $1.05M | $416055.00 | -$566749.00 | $105180.00 |
| SG&A Expenses | $540928.00 | $351012.00 | $320644.00 | $432644.00 |
| Operating Expenses | $1.62M | $791310.00 | -$254096.00 | $537824.00 |
| Total Costs & Expenses | $1.62M | $791310.00 | -$235983.00 | $555936.00 |
| Interest Income | $4318.00 | $6007.00 | $14987.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $2126.00 |
| Depreciation & Amortization | $21533.00 | $19019.00 | $18113.00 | $18112.00 |
| EBITDA | -$1.60M | -$772291.00 | $249253.00 | -$553904.00 |
| EBITDA Ratio | ||||
| Operating Income | -$3.30M | $0.00 | $235983.00 | -$555940.00 |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $3.35M | -$773441.00 | -$6080.00 | -$18205.00 |
| Income Before Tax | $49610.00 | -$773441.00 | $229903.00 | -$574141.00 |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$2.00 |
| Net Income | $49610.00 | -$773441.00 | $229903.00 | -$574141.00 |
| Net Income Ratio | ||||
| EPS | $0.008 | -$0.17 | $0.05 | -$0.13 |
| Diluted EPS | $0.007 | -$0.17 | $0.05 | -$0.13 |
| Weighted Avg Shares Outstanding | $6.17M | $4.46M | $4.46M | $4.46M |
| Weighted Avg Shares Outstanding (Diluted) | $6.64M | $4.65M | $4.65M | $4.46M |
Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$3.30M in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.60M. Net income rose to $49610.00, keeping EPS at $0.008. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan